Colinearity of Reverse Transcriptase Inhibitor Resistance Mutations Detected by Population-Based Sequencing

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 4, 2003, Pages 398-402

  Gonzales, Matthew J ^a   Johnson, Elizabeth ^a   Dupnik, Kathryn M ^a   Imamichi, Tomozumi ^b   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Clone; Drug resistance; Genome; HIV 1; Reverse transcriptase

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NUCLEOTIDYLTRANSFERASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMA; POPULATION RESEARCH; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS GENOME; VIRUS ISOLATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

EID: 0345687956     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200312010-00006     Document Type: Article

References (23)

1. Imamichi T, Berg SC, Imamichi H, et al. Relative replication fimess of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J Virol. 2000;74:10958-10964.
2. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
3. Shulman NS, Hughes MD, Winters MA, et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr. 2002;31:121-127.
4. Lu B, Hellmann NS, Bates M, et al. Determination of clinical cut-offs for reduced response to tenofovir DF therapy in antiretroviral-experienced patients. Antivir Ther. 2002(Suppl);7:S137.
5. Calvez V, Costagliola D, Descamps D, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther. 2002;7:211-218.
6. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol. 2000;49:41-66.
7. Quinones-Mateu ME, Arts EJ. Fimess of drug resistant HIV-1: methodology and clinical implications. Drug Resist Update. 2002;5:224-233.
8. St. Clair M, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-1559.
9. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992;36:2664-2669.
10. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269:696-699.
11. White KL, Margot NA, Wrin T, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother. 2002;46: 3437-3446.
12. Devereux HL, Loveday C, Youle M, et al. Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. J Infect Dis. 2000;181:1804-1807.
13. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol. 2001;75:6410-6417.
14. Bleiber G, Munoz M, Ciuffi A, et al. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol. 2001;75:3291-3300.
15. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-8276.
16. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44:2475-2484.
17. Shafer RW, Warford A, Winters MA, et al. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods. 2000;86:143-153.
18. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002; 18:243-248.
19. Kearney M, Palmer S, Maldarelli F, et al. Comparison of single-genome sequencing with standard genotype analysis for detection of HIV-1 drug resistance mutations. Antivir Ther. 2003;8:S96.
20. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
21. Wrobel JA, Conrad MJ, Bloedon E, et al. Analysis of HIV type 1 reverse transcriptase: comparing sequences of viral isolates with mutational data. AIDS Res Hum Retroviruses. 2000; 16:2049-2054.
22. Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000;44:568-573.
23. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS. 2003;17:791-799.